1. Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of
Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017;153:420–429.
2. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of
Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut 2017;66:6–30.
4. Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of
Helicobacter pylori infection in Korea, 2013 revised edition. Korean J Gastroenterol 2013;62:3–26.
5. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of
Helicobacter pylori infection. Digestion 2013;88:33–45.
6. Lee JY, Kim N, Nam RH, In Choi S, Lee JW, Lee DH. Primary and secondary antibiotic resistance of
Helicobacter pylori in Korea from 2003 to 2018. Helicobacter 2019;24:e12660.
8. Kim BJ, Lee H, Lee YC, et al. Ten-day concomitant, 10-day sequential, and 7-day triple therapy as first-line treatment for
Helicobacter pylori infection: a nationwide randomized trial in Korea. Gut Liver 2019;13:531–540.
10. Choi HS, Park DI, Hwang SJ, et al. Double-dose, new-generation proton pump inhibitors do not improve
Helicobacter pylori eradication rate. Helicobacter 2007;12:638–642.
11. Kim BG, Lee DH, Ye BD, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for
Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007;12:31–35.
12. Kim SY, Lee SW, Jung SW, et al. Comparative study of
Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study. Helicobacter 2008;13:282–287.
13. Kim N, Park SH, Seo GS, et al. Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for
Helicobacter pylori eradication in Korea. Helicobacter 2008;13:542–549.
14. Choi WH, Park DI, Oh SJ, et al. Effectiveness of 10 day-sequential therapy for
Helicobacter pylori eradication in Korea. Korean J Gastroenterol 2008;51:280–284.
15. Kim MN, Kim N, Lee SH, et al. The effects of probiotics on PPI-triple therapy for
Helicobacter pylori eradication. Helicobacter 2008;13:261–268.
16. Jung JM, Shim KN, Oh HJ, et al. Role of anti-secretory treatment in addition to
Helicobacter pylori eradication triple therapy in the treatment of peptic ulcer. Korean J Gastroenterol 2008;51:11–18.
19. Song MJ, Park DI, Park JH, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of
Helicobacter pylori. Helicobacter 2010;15:206–213.
20. Kim YS, Kim SJ, Yoon JH, et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for
Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011;34:1098–1105.
21. Choi KH, Chung WC, Lee KM, et al. Efficacy of levofloxacin and rifaximin based quadruple therapy in
Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci 2011;26:785–790.
22. Chung JW, Jung YK, Kim YJ, et al. Ten-day sequential versus triple therapy for
Helicobacter pylori eradication: a prospective, open-label, randomized trial. J Gastroenterol Hepatol 2012;27:1675–1680.
23. Choi HS, Chun HJ, Park SH, et al. Comparison of sequential and 7-, 10-, 14-d triple therapy for
Helicobacter pylori infection. World J Gastroenterol 2012;18:2377–2382.
24. Park HG, Jung MK, Jung JT, et al. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for
Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther 2012;35:56–65.
25. Oh HS, Lee DH, Seo JY, et al. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J Gastroenterol Hepatol 2012;27:504–509.
26. Kim SY, Jung SW, Kim JH, et al. Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for
Helicobacter pylori infection in Korea. Br J Clin Pharmacol 2012;73:140–143.
27. Lee HJ, Kim JI, Cheung DY, et al. Eradication of
Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis 2013;208:1123–1130.
28. Kim SY, Lee SW, Hyun JJ, et al. Comparative study of
Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy. J Clin Gastroenterol 2013;47:21–24.
29. Heo J, Jeon SW, Jung JT, et al. A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for
Helicobacter pylori eradication. Dig Liver Dis 2014;46:980–984.
30. Park CS, Lee SM, Park CH, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for
Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol 2014;109:1595–1602.
31. Lee JW, Kim N, Kim JM, et al. A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for
Helicobacter pylori infection in Korea. Scand J Gastroenterol 2014;49:917–924.
32. Lee HJ, Kim JI, Lee JS, et al. Concomitant therapy achieved the best eradication rate for
Helicobacter pylori among various treatment strategies. World J Gastroenterol 2015;21:351–359.
33. Bang CS, Kim YS, Park SH, et al. Additive effect of pronase on the eradication rate of first-line therapy for
Helicobacter pylori infection. Gut Liver 2015;9:340–345.
34. Chung JW, Han JP, Kim KO, et al. Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for
Helicobacter pylori eradication: a multicenter, prospective study. Dig Liver Dis 2016;48:888–892.
36. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of
Helicobacter pylori infection. Am J Gastroenterol 2017;112:212–239.
37. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of
Helicobacter pylori infection in adults. Gastroenterology 2016;151:51–69; e14.
38. Graham DY. Transitioning of
Helicobacter pylori therapy from trial and error to antimicrobial stewardship. Antibiotics (Basel) 2020;9:671.
39. Lee JH, Ahn JY, Choi KD, et al. Nationwide antibiotic resistance mapping of
Helicobacter pylori in Korea: a prospective multicenter study. Helicobacter 2019;24:e12592.